Evidence map›Paper›PMID 36189360›Full record

ArticleFrontiers in cellular and infection microbiology2022

Changes in the seroprevalence and risk factors between the first and second waves of COVID-19 in a metropolis in the Brazilian Amazon.

Maria Karoliny da Silva Torres, Felipe Teixeira Lopes, Aline Cecy Rocha de Lima, Carlos Neandro Cordeiro Lima, Wandrey Roberto Dos Santos Brito, Janete Silvana S Gonçalves, Onayane Dos Santos Oliveira, Vanessa de Oliveira Freitas, Bernardo Cintra Dos Santos, Renata Santos de Sousa and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Maria Karoliny da Silva TorresLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Felipe Teixeira LopesLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Aline Cecy Rocha de LimaLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Carlos Neandro Cordeiro LimaLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Wandrey Roberto Dos Santos BritoLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Janete Silvana S GonçalvesLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Onayane Dos Santos OliveiraLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Vanessa de Oliveira FreitasLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Bernardo Cintra Dos SantosLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Renata Santos de SousaLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Jayanne Lilian Carvalho GomesLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Bruno José Sarmento BotelhoLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Ana Carolina Alves CorreaLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Luiz Fernando A MachadoLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Rosimar Neris Martins FeitosaLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Sandra Souza LimaLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Izaura Maria Vieira Cayres VallinotoLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Antonio Carlos R VallinotoLaboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Universidade Federal do Pará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Brazil, the coronavirus disease 2019 (COVID-19) epidemic spread rapidly in a heterogeneous way, mainly due to the different socioeconomic and behavioral characteristics of different regional populations and different evaluation periods. We performed a cross-sectional study including 1,337 individuals (first wave = 736/second wave = 601) after the first two waves of COVID-19 in the city of Belém, the capital of the state of Pará. The detection of IgG anti-SARS-CoV-2 antibodies was performed using an enzyme-linked immunosorbent assay test followed by statistical analysis using the RStudio program. Our results showed an increase in the seroprevalence (first wave= 39.1%/second wave= 50.1%) of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG antibodies in the population of Belém from the first to the second pandemic wave. Advanced age, primary or secondary education level, lack of social isolation, and a low frequency of protective mask use were considered risk factors for SARS-CoV-2 infection during the first wave compared to the second wave. This study is one of the firsts to provide important information about the dynamics of virus circulation and the groups vulnerable to exposure in the two major periods. Our data emphasize the socioeconomic characteristics of the affected population and that nonpharmacological prevention measures are crucial for combating the pandemic.

Indexed as

COVID-19Antibodies, ViralBrazilCross-Sectional StudiesHumansImmunoglobulin GRisk FactorsSARS-CoV-2Seroepidemiologic StudiesAntibodies, ViralImmunoglobulin GAmazonBelémBrazilCOVID-19SARS-CoV-2seroepidemiology

Identifiers

PMID36189360
PMCPMC9524613
OpenAlexW4297445411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.